Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture

Neural Regeneration Research

Volumn 9, Issue 24, 2014, Pages 2128-2131

  Oda, Akira ^a   Tanaka, Hidekazu ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

Alzheimer s disease (AD); Cholinergic system; Cognition; Dendritic spine remodeling; Nicotinic acetylcholine receptors (nAChRs); Synaptic morphology; Synaptic plasticity; Synaptic transmission

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [(5 PHENYL 1,3,4 THIADIAZOL 2 YL)OXY] 1 AZONIATRICYCLO[3.3.1.1 3,7]DECANE 3,4 DICARBOXY 3 HYDROXYBUTANOATE; A 81418; ABT 107; ABT 560; ABT PR1; ABT PR2; AMYLOID PROTEIN; AQW 051; AR R 23465XX; AZD 0328; AZD 1446; BRADANICLINE; BUNGAROTOXIN RECEPTOR; ENCENICLINE; FACINICLINE; GLUTAMIC ACID; ISPRONICLINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; POZANICLINE; TC 6683; UNCLASSIFIED DRUG; VARENICLINE;

ACTION POTENTIAL; ALZHEIMER DISEASE; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONNECTOME; DEMENTIA; DENDRITIC SPINE; DOWN REGULATION; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC SYSTEM; HUMAN; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; REVIEW; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS;

EID: 84921815940     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.147943     Document Type: Review

References (37)

1. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX (1999) Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 19: 2693-2705.
2. Ashby MC, Ibaraki K, Henley JM (2004) It's green outside: tracking cell surface proteins with pH-sensitive GFP. Trends Neurosci 27: 257-261.
3. Ballesteros-Yanez I, Benavides-Piccione R, Bourgeois JP, Changeux JP, DeFelipe J (2010) Alterations of cortical pyramidal neurons in mice lacking high-affinity nicotinic receptors. Proc Natl Acad Sci U S A 107: 11567-11572.
4. Burghaus L, Schutz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schroder H (2000) Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76: 385-388.
5. Champtiaux N, Changeux JP (2004) Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog Brain Res 145: 235-251.
6. Dan Y, Poo MM (2004) Spike timing-dependent plasticity of neural circuits. Neuron 44: 23-30.
7. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70: 439-446.
8. Dineley KT (2007) Beta-amyloid peptide-nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front Biosci 12: 5030-5038.
9. Drevets WC, Zarate CA, Jr., Furey ML (2013) Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 73: 1156-1163.
10. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV (1998) Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18: 1187-1195.
11. Ge S, Dani JA (2005) Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. J Neurosci 25: 6084-6091.
12. Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27: 482-491.
13. Gu Z, Yakel JL (2011) Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 71: 155-165.
14. Halff AW, Gomez-Varela D, John D, Berg DK (2014) A novel mechanism for nicotinic potentiation of glutamatergic synapses. J Neurosci 34: 2051-2064.
15. Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 137: 22-54.
16. Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST (2009) Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 66: 646-651.
17. Ji D, Lape R, Dani JA (2001) Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31: 131-141.
18. Kessels HW, Malinow R (2009) Synaptic AMPA receptor plasticity and behavior. Neuron 61: 340-350.
19. Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, Jacobsen J (2014) Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 37: 232-245.
20. Lin H, Vicini S, Hsu FC, Doshi S, Takano H, Coulter DA, Lynch DR (2010) Axonal alpha7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proc Natl Acad Sci U S A 107: 16661-16666.
21. Lozada AF, Wang X, Gounko NV, Massey KA, Duan J, Liu Z, Berg DK (2012a) Induction of dendritic spines by beta2-containing nicotinic receptors. J Neurosci 32: 8391-8400.
22. Lozada AF, Wang X, Gounko NV, Massey KA, Duan J, Liu Z, Berg DK (2012b) Glutamatergic synapse formation is promoted by alpha7-containing nicotinic acetylcholine receptors. J Neurosci 32: 7651-7661.
23. McKinney RA (2010) Excitatory amino acid involvement in dendritic spine formation, maintenance and remodelling. J Physiol 588: 107-116.
24. Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49: 200-210.
25. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6: 78-87.
26. Oda A, Yamagata K, Nakagomi S, Uejima H, Wiriyasermkul P, Ohgaki R, Nagamori S, Kanai Y, Tanaka H (2014) Nicotine induces dendritic spine remodeling in cultured hippocampal neurons. J Neurochem 128: 246-255.
27. Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y (2013) Alterations in alpha4beta2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Brain 136: 3004-3017.
28. Okamura K, Tanaka H, Yagita Y, Saeki Y, Taguchi A, Hiraoka Y, Zeng LH, Colman DR, Miki N (2004) Cadherin activity is required for activity-induced spine remodeling. J Cell Biol 167: 961-972.
29. Patel SS, Attard A, Jacobsen P, Shergill S (2010) Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature. BMC Psychiatry 10: 69.
30. Placzek AN, Zhang TA, Dani JA (2009) Nicotinic mechanisms influencing synaptic plasticity in the hippocampus. Acta Pharmacol Sin 30: 752-760.
31. Radcliffe KA, Fisher JL, Gray R, Dani JA (1999) Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann N Y Acad Sci 868: 591-610.
32. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145.
33. Rousseau SJ, Jones IW, Pullar IA, Wonnacott S (2005) Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro. Neuropharmacology 49: 59-72.
34. Sabri O, Kendziorra K, Wolf H, Gertz HJ, Brust P (2008) Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 35 Suppl 1: S30-45.
35. Scarr E, Gibbons AS, Neo J, Udawela M, Dean B (2013) Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci 7: 55.
36. Tada T, Sheng M (2006) Molecular mechanisms of dendritic spine morphogenesis. Curr Opin Neurobiol 16: 95-101.
37. Wess J (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44: 423-450.